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Abstract
There have been significant improvements in the detec-
tion and treatment of breast cancer in recent decades. 
However, there is still a need to develop more effective 
therapeutic techniques that are patient specific with 
reduced toxicity leading to further increases in patients’ 
overall survival; the ongoing progress in understand-
ing recurrence, resistant and spread also needs to be 
maintained. Better understanding of breast cancer pa-
thology, molecular biology and progression as well as 
identification of some of the underlying factors involved 
in breast cancer tumourgenesis and metastasis has led 
to the identification of novel therapeutic targets. Over 
a number of years interest has risen in breast tumour 
kinase (Brk) also known as protein tyrosine kinase 6; 
the research field has grown and Brk has been de-
scribed as a desirable therapeutic target in relation to 
tyrosine kinase inhibition as well as disruption of its 
kinase independent activity. This review will outline the 
current “state of play” with respect to targeted therapy 
for breast cancer, as well as discussing Brk’s role in the 
processes underlying tumour development and metas-
tasis and its potential as a therapeutic target in breast 
cancer.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Breast tumour kinase/protein tyrosine kinase 
6 is overexpressed in up to 86% of invasive breast can-
cers. It plays a key role in regulating a number of cell 
processes that are involved in the metastatic process. 
As a kinase involved in both epidermal growth factor 
and insulin like growth factors signaling, inhibiting its 
activity could prove to be an effective way to enhance 
the effects of current targeted treatments. In addition, 
disrupting the protein-protein interactions central for 
the kinase-independent aspects of its function may 
generate an alternative mechanism for selective target-
ing of breast cancer cells.
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INTRODUCTION
Exactly how breast cancer therapeutics has changed 
over the years is an intriguing aspect of  the progress 
and evolution that has been made in research for can-
cer cures and treatments. Looking at the incidence and 
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mortality rates over the years in the United Kingdom and 
worldwide indicates the significant impact that contin-
ued improvements in detection and treatment of  breast 
cancer have made. Statistically breast cancer incidence 
rates have been increasing since the 1970s[1]. Approxi-
mately 75000 cases of  breast cancer were diagnosed in 
1975 compared to approximately 126000 in 2010[1]. The 
increased frequency may be due to improved diagnostic 
techniques that contribute towards the rise in incidence; 
thus detecting cancers that may have remained unnoticed 
until much later. Breast cancer is the most common can-
cer in the United Kingdom with more than 48000 people 
being diagnosed each year[1] and is the most recognized 
cause for the mortality rates of  women aged between 33 
and 55. This indicates room for improvement in relation 
to enhanced and effective therapeutic techniques that 
are patient specific, relatively non-toxic and contribute 
towards patients overall survival. Not only that, but there 
is ongoing progress needed towards understanding recur-
rence, resistant and spread[2] .
A closer look at breast cancer pathology, molecular 
biology and progression may lead to a better understand-
ing of  the underlying factors involved in breast cancer 
tumourgenesis and metastasis. A particular interest has 
risen in breast tumour kinase (Brk) also known as protein 
tyrosine kinase 6 (PTK6). Over a number of  years the 
Brk research field has grown and Brk has been hinted at, 
as being a desirable therapeutic target in relation to tyro-
sine kinase inhibition as well as disruption of  its kinase 
independent activity. Here, we outline Brk’s role in the 
pathways essential for breast tumour development and 
discuss its potential as a therapeutic target in breast can-
cer.
BRK
Brk, also known as PTK6, was originally identified in a 
study involving human melanocytes and subsequently 
isolated from breast cancer cell lines in a study identifying 
novel kinases with therapeutic potential[3]. The ptk6 gene 
encodes the non-receptor tyrosine kinase, which consists 
of  SH2, SH3 a linker region and catalytic domains. Total 
activity of  Brk is significantly higher in malignancy than 
in normal mammary tissue, and over-expression of  the 
protein has been noted in more than 80% of  invasive 
ductal breast tumors[4]. Brk expression so far has been 
detected in the majority of  breast cancer cell lines with 
differing intensities[5]. Gene sequencing indicated simi-
larities with the SRC-family of  protein tyrosine kinases, 
however there are distinct differences such as the lack of  
N-terminal extension and consensus sequences for fatty 
acylation and membrane association[6]. Furthermore, its 
genomic structure is quite distinct from the SRC-family 
PTKs, which demonstrates an evolutionary divergence[7]. 
Brk has also been shown to have a significant degree of  
similarity with the Drosophila src related gene known as 
Dsrc41, with six out of  seven of  Brk’s exon boundaries 
conserved with the Dsrc41 gene which has 9 exons. This 
could indicate Brk is likely to share a common ances-
tor with Dsrc41. The ptk6 gene comprises 8 exons and 
encodes a 451 amino acid protein and FISH studies indi-
cated localisation to chromosome 20q13.3[6]. The protein 
product has a predicted molecular weight of  50 kDa, 
which generally resolves to around 48 kDa on an SDS-
PAGE gel.
SH3 domains are small protein nodules made up of  
β-sheets. SH3 domains allow the assembly of  specific 
protein complexes via proline-rich peptide binding, re-
viewed in[8]. Brk’s SH2 and SH3 domains are used for 
substrate recognition[9,10]. The Brk SH3 domain has been 
known to undergo conformational changes due to pH 
fluctuations indicating that its structure could determine 
substrate and protein interaction, thus influencing its 
varied role in diverse cellular environments. The SH3 
domain may have a role in enzyme regulation[11]. The 
SH2 domain contains a/β folds and a phosphotyrosine 
binding surface with two a-helices opposite a central 
βa-sheet made up of  four anti-parallel strands[12]. This 
domain plays a role in protein-protein interactions and 
is important for regulation of  catalytic activity[10]. Due 
to the lack of  myristoylation and a nuclear localization 
sequence, Brk’s regulation is difficult to determine which 
allows for more flexibility with its subcellular localization, 
reviewed in[13].   
REASONS FOR NEW CANCER THERAPIES
Chemotherapy and radiotherapy have been recognised 
to target normal rapidly dividing cells such as bone mar-
row, gastrointestinal tract or hair follicles; the range and 
intensity of  adverse effects reduces the specificity and 
increases toxicity of  these therapies. Both these types of  
treatments therefore have a limited therapeutic index and 
can often be palliative in use as reviewed in[14]. Hormonal 
therapies have also been in use; for example Tamoxifen, 
which has been used for early stage and metastatic breast 
cancer since its licence in 1972[15]. Although proven to be 
effective against breast cancer, especially those that are 
oestrogen receptor positive, there are still many issues 
that need to be overcome for maximum effect of  the 
drug to be achieved, whether by itself  or as combination 
therapy. These include the diverse adverse toxicities such 
as thrombosis, strokes and development of  secondary 
cancers. Other issues include resistance against Tamoxi-
fen and subsequent recurrence in some patients. Further-
more, this drug is only effective against oestrogen or pro-
gesterone receptor positive breast cancers thus making it 
unsuitable for other types of  breast cancer such as HER2 
positive/ER/PR negative and triple negative breast 
cancers (reviewed in[16]). However there are treatments 
available for HER2 positive cancers such as Herceptin, a 
monoclonal antibody that binds to HER2 thus negatively 
effecting receptor function, as well as a number of  kinase 
inhibitors. Unfortunately the more advanced stages of  
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breast cancer do not always respond to Herceptin therapy 
and those that do, often progress in 12 mo from the start 
of  the treatment[17]. In addition resistance may occur due 
to the involvement of  a number of  signaling pathway 
molecules such as activation of  the PI3K/AKT pathway, 
loss of  PTEN and activation of  PIK3CA, reviewed in[18]. 
Brk is expressed in a wide range of  cancer types and its 
expression appears to be independent of  ER/PR/HER2 
positivity, thus making it an ideal candidate for therapeu-
tic intervention[5,19].
TYROSINE KINASE INHIBITION
Targeted therapy is largely directed specifically towards 
tumour cells thus reducing many side effects and provid-
ing a wider therapeutic window. They can also be used in 
combination with traditional chemotherapy or radiother-
apy to enhance anticancer effects. Further patient benefit 
includes convenience with oral consumption rather than 
intravenous administration as is the case for many che-
motherapy drugs.
Tyrosine kinases have been implicated in a range of  
cancers; they are involved in cellular signalling and play 
an important role in growth factor signalling. In their 
active forms tyrosine kinases can promote tumour cell 
proliferation, growth and induce anti-apoptotic effects, as 
well as promote angiogenesis and tumour cell metastasis. 
Since most of  these cellular events contribute to tumour 
progression and decreased patient prognosis, tyrosine ki-
nases are considered ideal candidates for targeted therapy.
There are two main types of  kinases; these can be 
categorized as receptor protein kinases that are generally 
membrane spanning, or non-receptor protein kinases 
that relay intracellular signals from the receptors and, of  
which, Brk is one. Briefly, when ligands bind to their cog-
nate receptors, they stimulate receptor dimerization fol-
lowed by autophosphorylation and activation of  tyrosine 
kinase activity. As a result, multiple signalling pathways 
are activated and intracellular mediators in these pathways 
transduce signals from membrane receptors through the 
cytosol and into the nucleus which ultimately alters DNA 
synthesis and cell division as well as a wide range of  bio-
logical processes as reviewed in[14]. Protein tyrosine kinase 
activity within breast tumour tissues has been reported 
to be significantly higher in comparison with benign or 
normal breast tissues[20]. For example, the tyrosine kinase 
activity of  the product of  c-src proto-oncogene has been 
found to be elevated in human breast tumors[21], and sev-
eral tyrosine kinase receptors have also been implicated in 
breast cancer development and progression. 
These include members of  the erbB Type 1 trans-
memebrane receptor family such as epidermal growth 
factor receptor (EGFR) and HER2/neu transmembrane 
tyrosine kinase receptor, as well as receptors for insulin 
like growth factors (IGF) such as IGF-1R[22,23]. Others 
include fibroblast growth factor receptor[24] and met re-
ceptor tyrosine kinase[25]. Of  the substrates and proteins 
interacting with Brk[13], many are linked to signalling from 
these receptors, thus indicating a role for Brk in these sig-
nalling pathways.
EXAMPLES OF TYROSINE KINASE 
INHIBITORS IN BREAST CANCER-
LAPATINIB, ERLOTINIB AND GETFINTIB
Gefitinib is an EGFR inhibitor, the first of  its kind, that 
is also known to have an effect in HER2-overexpressing 
cell lines probably due to the reduction in phosphoryla-
tion of  HER2/EGFR heterodimer[26]. Gefitinib is espe-
cially effective in ER-positive and Tamoxifen resistant tu-
mours indicating a target group of  patients for this type 
of  treatment[27]. Erlotinib works in much the same way as 
Gefitinib, as a reversible EGFR inhibitor. It is clinically 
effective in locally advanced and metastatic non-small cell 
lung cancer[28] but its benefit in breast is only recently be-
coming clearer, and there is some indication for Erlotinib 
in triple negative breastcancers[29]. Erlotinib inhibits triple 
negative breast cancer as shown by Ueno and Zhang[30] 
when they generated a SUM149 xenograft model by 
implanting luciferase expressing SUM149 cells into mam-
mary pads of  athymic nude mice. The results indicated 
significant inhibition of  tumour growth at doses of  50 
and 100 mg/kg.
There is a strong correlation between HER2 and 
EGFR in terms of  dimerization, expression as well as 
activity[31] since HER2 is EGFR’s most common het-
erodimerization partner and HER2 potentiates EGFR 
signalling by enhancing EGF binding affinity[32]. A dual 
inhibitor for HER2 and EGFR may therefore be of  
greater clinical benefit than individual therapies. When us-
ing an inhibitor with a single mode of  action, therapeutic 
resistance can be increased whereas dual inhibition may 
reduce the chance of  this happening[32]. Other benefits 
of  dual inhibition may include targeting a wider range of  
cancers since single inhibitors are, in some cases, specific 
for one particular type of  cancer as well as a more effec-
tive inhibition in cancer cell growth overall[33].
One such inhibitor already in use is Lapatinib, which 
reversibly inhibits the tyrosine kinase activity of  both 
HER2 and EGFR, reviewed in[32]. It is an orally avail-
able inhibitor that binds to EGFR in its inactive form in 
comparison to other EGFR inhibitors such as Erlotinib 
and Geftinib, which bind EGFR in its active form. This 
allows for a greater duration of  effect at the target site[34]. 
So far Lapatinib has proven to be well tolerated with rare 
occurrences of  high-grade toxicities. In relation to Brk, 
Lapatinib has been recognised to have reduced efficacy 
with increased levels of  Brk in HER2-transfected mam-
mary epithelial cells[35]. This may suggest a role for Brk in 
acquired resistance against HER2 targeted therapy when 
both proteins are over-expressed. Targeting Brk alongside 
HER2 inhibition could overcome resistance as well as 
increase efficacy of  HER2-targetted treatment.
Both Gefitinib and Erlotinib initially indicated no real 
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HER2 is overexpressed in approximately 20%-30% 
of  breast cancers[44] and it has been suggested that Brk 
may be involved in regulation of  signal transduction from 
HER tyrosine kinases. Several studies have shown a link 
between HER2/neu expression and Brk/PTK6[35,45].
This is of  interest because, as discussed above, HER2 
targeted therapy although clinically proven to be effective 
does pose some restrictions such as lack of  effect in some 
HER2/neu positive cancers as well as resistance. There-
fore, Brk targeted therapy maybe of  clinical benefit espe-
cially when used in combination with existing HER2/neu 
targeted therapy. Due to the strong correlation between 
PTK6 and HER2, there is evidence suggesting that it may 
also be linked with prognosis thus indicating a role for 
Brk as a prognostic factor in breast cancer. PTK6 expres-
sion studied in 426 breast cancer cases further supports 
its potential as a independent prognostic factor regardless 
of  morphological and molecular markers such as lymph 
node involvement, tumour size and HER2 status[46]. Co-
expression of  Brk and HER2 has been linked to co-am-
plification of  both the ErbB2 and ptk6 genes[35], although 
this is not a consistent finding in other patient studies. It 
is worth noting that although HER2 is over expressed in 
20%-30% of  breast cancers[44], Brk is over expressed in 
upto 86% of  breast cancers[47], which indicates that in the 
majority of  breast cancers Brk is over expressed indepen-
dently of  HER2 status.
At a protein level, Aubele and colleagues showed that 
PTK6 forms protein complexes with HER2 in paraffin 
tissues from invasive breast carcinomas[48]. Recently, the 
effect of  simultaneous knockdown of  PTK6 and HER2 
has been analysed in the herceptin-resistant cell line 
JIMT-1[49]. The results indicated significant reduction in 
phosphorylation of  important signalling intermediates, 
namely MAPK, ERK and p38MAPK and PTEN, which 
are involved in tumourgenesis. Furthermore there was 
reduced migration and invasion of  JIMT-1 cells when 
expression of  both proteins was suppressed. HER2 may 
also be involved in elevating Brk levels via upregulating 
calpastatin and inhibiting calpain-1 activity in breast can-
cer cells[50].
These combined data further support the study of  
dual inhibition of  Brk and HER2, firstly for a greater 
clinical effect and secondly to overcome anti-HER2 ther-
apeutic resistance.
BRK AND EGFR INTERACTIONS
ErbB signalling in breast tumour progression has been 
extensively documented. EGFR tyrosine kinases have 
been involved in regulation of  normal and abnormal 
cellular proliferation and survival (reviewed in[51]). Both 
EGFR and HER2 are intrinsically linked; HER2 potenti-
ates EGFR signalling by enhancing binding ability of  
EGF and reducing its degradation and studies have indi-
cated that HER2 signalling is reduced via EGFR-specific 
inhibitors[52].
clinical benefit for metastatic breast cancer patients and 
had little efficacy in phase Ⅱ studies[27]. This indicates 
lack of  correlation between EGFR expression level with 
response to treatment even though many breast can-
cer cells express EGFR[36]. Previously there was strong 
evidence for combination therapy with tyrosine kinase 
inhibitors and hormone therapy[32], thus allowing for a 
greater clinical benefit. However more recently, combina-
tion therapy using Geftinib and anti-hormonal therapy 
(fulvestrant and anastrozole) demonstrated only a modest 
increase in clinical benefit compared to Geftinib or hor-
monal therapy alone[37].
Erlotinib resistance is linked to CDK2 activity; cell 
proliferation is induced in Erlotinib treated cells when 
CDK2 is expressed and, conversely, there is increased 
sensitivity to Erlotinib when CDK2 activity is sup-
pressed. Erlotinib has also shown to upregulate p27 and 
nuclear translocation in association with cell growth inhi-
bition in non-small cell lung cancer[38]. Cyclin dependent 
kinases regulate cell cycle progression from quiescence to 
mitosis by activating the transcription factor E2F leading 
to activation of  genes needed for progression from G1 
to S phase[36]. Furthermore, in relation to breast cancer it 
has been shown that inhibition of  the erbB2 pathway by 
EGFR inhibitors in erbB2-overexpressing breast cancer 
cell lines caused G1 phase arrest with accumulation of  
p27 and reduced Cyclin D1[39]. This is further verified by 
Nahta et al[40] who showed that downregulation of  p27 
in breast cancer cells was accompanied by an increased 
S-phase fraction and increased resistance to Herceptin 
therapy. The induction of  p27 is therefore necessary in 
Erlotinib inhibition of  cell growth.
Since cell cycle deregulation is implicated in develop-
ment of  neoplasia and may contribute towards develop-
ment of  breast cancer, as well as response to therapy the 
discovery that Brk is involved in cell cycle regulation was 
of  importance[41]. Brk deregulates cell cycle progression; 
an inverse correlation was shown between Brk expression 
levels and p27 expression levels. With increasing Brk ex-
pression there was reduced p27, and in cells lacking p27 
and Fox03a, Brk induced a decreased level of  cell prolif-
eration indicating it may need the p27/Fox03a pathway 
to promote cell growth. This indicates the importance of  
Brk’s role in cell cycle progression and suggests a role for 
Brk in mediating cell responses to EGFR/HER2 inhibi-
tors through regulation of  p27.
BRK AND HER2 INTERACTIONS
In cancer cells, alterations in HER receptors or in their 
downstream signalling components are known to occur; 
HER2 is a negative prognostic factor, the presence of  
which indicates aggressive phenotype and reduced overall 
survival rate as reviewed in[42], although it should be noted 
that survival rates for HER2 positive cancers are improv-
ing due to the introduction of  targeted therapies[43].
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The EGF receptor family are linked to the tumour-
genic transformation of  breast epithelial cells. When Brk 
Transfected mammary epithelial cell lines, MCF10A and 
Hb4a, were treated with human growth factors (EGF), 
mitogenic activity of  Brk was observed. This reveals Brk’
s role in sensitizing human mammary epithelial cells to 
growth factors such as EGF[53]. Furthermore, Brk as-
sociation with the EGF receptor has also been detected, 
even in the absence of  EGF, leading to proliferation 
of  epithelial cells. EGFR expression also plays a role in 
keratinocyte differentiation[54], a process in which Brk is 
involved[55]. Inhibition of  EGFR signalling during differ-
entiation induces growth arrest, however Brk’s promotion 
of  EGFR signalling suggests that one of  its roles may in-
volve promoting cell survival during early differentiation.
EGF stimulation results in rapid phosphorylation of  
Brk indicating the involvement of  Brk in the EGF signal-
ling complex[56]. EGF binding to its receptor, EGFR, not 
only induces its phosphorylation but also the phosphory-
lation of  other EGFR family members (HER2, 3 and 
4). The expression of  Brk therefore not only increases 
phosphorylation of  EGFR and HER2 but also of  HER3 
(erbB3) in breast cell lines[56]. It may do this via direct in-
teraction with an erbB3-containing complex in response 
to EGF stimulation. Brk’s ability to enhance EGFR sig-
nalling could be mediated by inhibition of  EGFR down-
regulation[57], which is achieved by phosphorylation of  
either ARAP-1[58] or c-Cbl[59], thereby prolonging EGFR 
signalling.
Expression of  Brk enhances EGF-induced ErbB3 
phosphorylation and recruitment of  P13K to ErbB3 
thus inducing P13K activity[56]. Since the P13K pathway 
is implicated in breast cancer and is linked with resistance 
to HER2 targeted therapies, its interaction with Brk 
may give a wider overview of  the mechanisms involved 
in developing resistance. P13K has been a desirable 
therapeutic target of  its own and current therapies, as 
reviewed in[60], focus on anti-mTOR agents, tyrosine ki-
nase inhibitors and P13K inhibitors. However to create a 
greater clinical effect, combinations of  these treatments 
including a potential Brk tyrosine kinase inhibitor maybe 
more useful and reduce the activation of  compensatory 
feedback loops which could decrease efficacy of  single 
agents. Since Akt is a known substrate of  Brk, and Brk 
negatively regulates its phosphorylation in epithelial cells, 
the potential consequences of  this therapy may need 
to be fully assessed[61]. Nonetheless, due to most of  the 
normal cells that express Brk being outside the prolifera-
tive areas of  the tissues Brk targeted therapy may still be 
highly specific[62].
Overall Brk has shown to prolong EGFR signal-
ling, sensitise tumour cells to EGF stimulation, inhibit 
degradation of  EGFR and reduce sensitivity of  EGFR 
inhibitors in Brk overexpressing cells. This suggests Brk 
inhibiton could reduce tumour proliferation and growth 
via reduced EGFR signalling and increase EGFR inhibi-
tor sensitivity. 
BRK AND IGF INTERACTIONS
Insulin receptor substrate 4 (IRS-4) is part of  the insu-
lin receptor substrate family, which also contains IRS-1, 
IRS-2 and IRS-3. Their function includes a variety of  
biological effects such as cell proliferation, growth, 
survival and differentiation downstream of  insulin and 
insulin-like growth factor 1 (IGF-1) receptors[63]. IRS-4, 
upon IGF-1 stimulation, is phosphorylated which leads 
it to binding to P13K activating the MAPK pathway. The 
link between insulin-like growth factor (IGF) and breast 
cancer has been well documented; the IGF-1 receptor 
is significantly overexpressed in tumour cell lines com-
pared to normal breast cancer epithelial tissue and benign 
tumours[64] and there is also a clear correlation between 
poor breast cancer prognosis and overexpression of  
IGF-1R[65]. In the MCF-7 breast carcinoma cell line, IGF 
stimulation results in Akt activation leading to cell pro-
liferation through phosphorylation of  Raf  kinase. Along 
with this, IGF stimulation leads to resistance to anoikis[66], 
a process whereby epithelial cells undergo apoptosis due 
to loss of  interaction with neighbouring cells and the 
basement membrane[67]. Overexpression of  IGF-1R is 
also implicated in resistance against breast cancer therapy, 
especially against Herceptin[17].
Immunoprecipation and mass spectrometry have 
shown IRS-4 substrate interaction with Brk in co-
transfected HEK 293 cells[68]. In addition to this interac-
tion with IRS-4, Brk also co-precipitates with IRS-1 and 
IGF-IR[66]. The interaction of  Brk with IGF-IR as well 
as EGFR and HER2 gives an indication of  the range of  
Brk activity in regulating signalling. EGFR, HER2 and 
IGF-1R are overexpressed in different subsets of  breast 
cancers whereas Brk is overexpressed in majority of  
breast cancers and has a role in each of  these signalling 
pathways, thus making it an attractive therapeutic target 
for disrupting signalling cross-talk. Since Brk interacts 
with IGF-1R, disrupting this association may also reduce 
the chance of  developing resistance against current breast 
cancer therapies such as Herceptin, through HER2-
IGF-R1 heterodimer formation resulting in phosphoryla-
tion and activation of  HER2 as reviewed in[69].
BRK AND ITS INTERACTION 
ALTERNATIVELY SPLICED ISOFORM, 
ALT-PTK6
During the characterisation and chromosome mapping 
of  Brk, an alternatively spliced short isoform was identi-
fied in T47D cells, which was originally called λm5 and 
then later renamed to ALT-PTK6[6,70]. ALT-PTK6 is 134 
amino acids in size (15 kDa) and is expressed from an 
alternatively spliced transcript that has a 122 base pair 
deletion at the 3’ end of  the SH3 coding region; thus it 
lacks the SH2 and kinase domains and has an alternative 
C-terminal proline rich sequence (Figure 1). The protein 
303 August 10, 2014|Volume 5|Issue 3|WJCO|www.wjgnet.com
Hussain HA et al . Breast cancer therapy: Brk’ potential role
level of  ALT-PTK6 was lower than full length Brk in 
T47D breast cancer cells[6]. There is still speculation of  
the role of  ALT-PTK6 and the extent of  its effect in the 
overall process of  cancer pathology, however, there has 
been indication that the short isoform may act as a com-
petitive inhibitor for the SH3 binding partners[70] since 
both contain the SH3 domain[6].
The Tyner laboratory were the first to describe a func-
tion of  ALT-PTK6, albeit in prostate cancer cell lines[70]. 
β-catenin has been identified as a direct substrate of  
Brk[71] and ALT-PTK6 may influence Brk’s ability to regu-
late β-catenin/TCF transcription[70]. The Wnt/β-catenin 
pathway promotes cancer cell growth and its deregulation 
is involved in pathogenesis of  various cancers including 
breast cancer, reviewed by[72]. ALT-PTK6 has also been 
shown to inhibit the phosphorylation of  Brk to some 
extent, since the presence of  ALT-PTK6 reduced PTK6 
interaction with tyrosine-phosphorylated proteins in what 
appears to be a dose-dependent manner[70].
Further to this, in co-transfection experiments, increased 
ALT-PK6 expression resulted in an increase of  constitu-
tively active form of  Brk in the nucleus with a decreased 
proportion at the membrane[70]. There was also reduced 
proliferation in ALT-PTK6 expressing prostate tumour cells 
compared to those without this short isoform. These data 
therefore suggest that ALT-PTK6 may contribute towards 
limiting Brk localisation to the nucleus and acting as a com-
petitive inhibitor thus reducing the ability of  Brk to interact 
with its substrates that promote tumour cell growth.
The localisation of  Brk therefore may play an impor-
tant role in development of  cancer since Brk’s arrange-
ment in the cellular environment may affect it’s role due 
to the variety of  substrates available in nucleus and cyto-
plasm[13]. Also Brk’s role in various tissue types has shown 
to be dramatically different, for example, in normal tis-
sues it is involved in regulation of  differentiation process 
whereas in tumour cells it promotes cell proliferation and 
survival.  Therefore, Brk’s function may depend on the 
tissue it is expressed in, its intracellular location and the 
substrate it interacts with[70]. 
BRK’S ROLE IN CELL MIGRATION, 
TUMOUR FORMATION AND 
METASTASIS 
To a large extent Brk is involved in breast cancer cell 
proliferation[73], however it is also involved in cell mi-
gration. A reduced ability for T47D and JIMT-1 breast 
cancer cell migration was observed in response to Brk 
suppression[49]. Paxillin is a multidomain protein that is 
recruited to edges of  the cell once migration is initiated, 
as reviewed in[74], and Brk has been recognised as a novel 
paxillin tyrosine kinase that binds to, as well as phos-
phorylates, paxillin[75]. Brk also acts a mediator of  EGF-
induced paxillin phosphorylation, thus promoting activa-
tion of  Rac1 and stimulating cell migration and invasion. 
KAP3A is a subunit of  the kinesin-2 heterotrimeric com-
plex and binds microtubule-based subunits KIF3A/3B to 
various cargo proteins, which enable membrane morpho-
genesis[76]. KAP3A has also been identified as a substrate 
of  Brk and is phosphorylated at its C-terminus, a process 
required for Brk-induced cell migration[77]. Along with 
this, p190, another substrate of  Brk, once phosphory-
lated is associated with p120 leading to Rho inactivation 
and Ras activation[78]. Migratory effects of  Brk are greatly 
impaired in cells lacking p190. These interactions indicate 
an important function of  Brk in regulating tumour cell 
migration via various systems, thus a Brk-targeted therapy 
could potentially cause disruption in these processes.
STAT3 and STAT5 are also recognised as substrates 
of  Brk and are involved in cellular processes leading to 
cell proliferation, migration and survival[79-81]. STAT3 is 
regarded as an oncogene, with tyrosine phosphorylation 
of  STAT3 connected to breast cancer development as 
discussed in[79]. Activation of  STAT3 by Brk may contrib-
ute towards cell transformation and uncontrolled growth 
in early stages of  breast cancer. Brk also mediates STAT3 
regulation in established tumours[80], and constitutive 
activation of  Brk accelerated cell migration and tumour 
growth in vivo[82].
Angiogenesis has been recognised as an essential 
process in survival of  cancerous cells in vivo; it is involved 
in tumour growth, progression and metastasis[83]. One 
of  the main pro-angiogenic factors involved in promot-
ing tumour angiogenesis is vascular endothelial factor 
(VEGF)[84]. Osteopontin is a secreted non-collagenous 
chemokine-like protein that regulates VEGF expression 
via a Brk/nuclear factor-kappaB (NF-κB)/ ATF-4 signal-
ling cascade[85]. Higher levels of  expression of  Brk, NF-
κB and ATF-4 correlated with higher tumour grades. As 
osteopontin is secreted from the bone and expressed in 
brain[86,87], which are frequent sites for breast cancer me-
tastasis[88], this study provides a mechanism whereby Brk 
could be involved in the formation of  metastases.
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Figure 1  Breast tumour kinase domain structure. Full length Brk/PTK6 
and short isoform ALT-PTK6 structure indicating the SH3 domain (green), SH2 
domain (orange) and a tyrosine kinase domain or proline rich sequence (blue). 
Underneath is indicated the cDNA structure of both forms, with each box indi-
cating each exon (total of 8 exons). ALT-PTK6 has deletion at exon 2 and lacks 
SH2 domain due to shift in open reading frame, which gives a proline rich se-
quence at exon 3 instead. PTK6: Protein tyrosine kinase 6; Brk: Breast tumour 
kinase.
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BRK AND CELL DEATH 
Brk’s proliferative ability when coupled with its ability to 
protect cancerous cells from cell death promotes tumour 
cell survival. Brk has shown association with the P13-K/
Akt pathway which is not only involved in cell prolifera-
tion but in apoptosis; thus activation of  this pathway 
may reduce the ability of  cells to undergo apoptosis[56]. 
Furthermore, Brk can protect breast cancer cells from 
autophagy; reduced expression of  Brk coupled with sus-
pension of  culture increased the number of  dead cells 
compared to controls[89]. Brk also increases phoshopory-
lation of  p38 MAPK which is associated with pro-sur-
vival cell phenotypes in breast cancer[90]. Brk’s ability to 
protect cancer cells from cell death is further enchanced 
due to  its ability to protect cells from DNA damage-
induced apoptosis in colon cancer cells.  Knockdown of  
Brk in HCT116 cells led to increased apoptosis following 
γ-irradiation[91]. In addition p53 was recognised as a pos-
sible positive regulator of  Brk/PTK6 activity in response 
to DNA damage. Reduced expression of  p21 and STAT3 
were also noticed in Brk-suppressed cells, leading to in-
creased apoptosis and decreased survival[91]. This gives 
indication for PTK6 inhibitors reducing tumour cell 
growth and survival. 
As discussed above, Brk also protected cells from 
anoikis via IGF-I signalling[66]. Further to this, recently 
PTK6 was described to protect cells from anoikis via di-
rect phosphorylation of  focal adhesion kinase (FAK) and 
activating Akt[92]. Knockdown of  PTK6 in PC3 prostate 
cancer cell line disrupted FAK and Akt activation which 
in consequence promoted anoikis thus indicating impor-
tant promotional role of  Brk in anchorage independent 
survival.
Within a different cellular context such as non trans-
formed rat fibroblasts, Brk has shown a role contradic-
tory to that seen in breast cancer since it sensitises cells 
to apoptosis[93]. Furthermore, it also promotes apoptosis 
in crypt epithelial cells in response to DNA damage[94]. 
This may show a role for Brk as a damage sensor that 
promotes apoptosis in response to cellular stress. These 
differences in Brk’s role may again depend on its cellular 
localisation, substrates and protein interaction as well as 
the tissue in which it is expressed[74].
FUTURE PERSPECTIVES 
Given that Brk’s roles extend to regulation of  several 
cancer hallmarks (Figure 2), Brk has promise as an ideal 
therapeutic target in breast cancer. Brk’s therapeutic po-
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tential could also extend to non-small cell lung cancer, 
prostate and colon cancer therapy[70,91,95]. 
It was recognised as one of  the tyrosine kinases ex-
pressed in breast cancer due to the immense interest in 
tyrosine kinase inhibitors[23]. So far tyrosine kinase inhibi-
tors have proven to be well tolerated with manageable 
side effects, selective and relatively effective in a range of  
cancers[97]. PTK6-null mice have shown to grow relatively 
healthily into adulthood indicating potential tolerability 
to Brk inhibitors in breast cancer patients[61]. These prop-
erties still make tyrosine kinase inhibition an attractive 
prospect despite Brk’s kinase independent functions. 
Nonetheless, many of  Brk’s activities involve its kinase 
catalytic domain including EGFR signalling, cell migra-
tion and cell death[13], thus targeting Brk’s kinase activity 
may still prove to be effective. Furthermore, in compari-
son to HER2, EGFR, IGFR and p53 its expression is 
much higher in many types of  breast cancer indicating 
targeting Brk may benefit a wider range of  patients[62].
Further study into the regulation of  Brk may provide 
greater understanding in its therapeutic value. So far stud-
ies focusing on discovery of  selective Brk inhibitors have 
shown effective inhibition with imidazo[1,2-a]pyrazin-8-
amines[98]. Recently, Brk’s importance in anti-cancer thera-
py was uncovered in a study involving heat shock protein 
90 (Hsp90) which has shown to regulate Brk since it is 
involved in folding and stability of  many proteins[99]. A 
potent Hsp90 inhibitor, geldanamycin decreased PTK6 
expression in T47D and BT474 cell lines indicating the 
requirement of  Brk’s interaction with Hsp90 for stability. 
Further investigations in a clinical setting regarding these 
therapies may show their efficacy in treating subtypes of  
breast cancers including triple negative basal like breast 
cancer.   
Brk has many substrates and protein interactions; 
some have been reported to require Brk’s kinase domain 
whereas others may require protein-protein interactions 
and some through indirect association via a third party[13]. 
Therefore, Brk kinase-independent activity does need 
consideration when looking at tyrosine kinase inhibitors. 
Interfering with Brk’s protein-protein interactions by dis-
rupting its conformational activation may also be thera-
peutically effective, including disruptions in the SH2 and 
SH3 domains[62]. 
Additionally, ALT-PTK6 the short isoform of  Brk 
may contribute towards its cellular localisation as increased 
ALT-PTK6 expression resulted in decreased Brk at the 
membrane and an increase in nuclear Brk[70]. Normally 
Brk is active in differentiating, non-dividing epithelial 
cells in the small intestine where it is a negative regula-
tor of  growth, however, due to an external stimuli such 
as DNA damage by irradiation, it contributes towards 
apoptosis[94]. This shows Brk’s differing role within the 
same tissue but in different conditions. Thus Brks func-
tions may also depend on external stimuli and the short 
isoform ALT-PTK6. This needs further investigation and 
clarification within breast cancers.
Brk’s role as a potential oncogene in relation to breast 
cancer is further supported by a recent study, which 
indicated Brk catalytically phosphorylated c-Cbl, a E3 
ubiquitin ligase that downregualtes oncoproteins, result-
ing in c-Cbl degradation via auto-ubiquitination[59]. Of  the 
multiple signalling pathways that Brk is involved in, this is 
yet another pathway in which Brk plays a key role thereby 
enhancing tumour survival. Therefore Brk’s involvement 
is extensive which suggests targeting Brk may allow tar-
geting of  a wider range of  pathways that lead to tumour 
growth, survival and progression.
In the immediate future, most progress could proba-
bly be made in combination treatments. Brk’s role in me-
diating cell responses to current EGFR/HER2 therapies 
is becoming known[35,49]. Further work in this area could 
pave the way for improvement to these therapies. Inves-
tigations into Brk’s role in tumour progression should 
allow for pre-clinical studies of  breast cancer metastasis 
and determine whether any therapeutic intervention has 
potential clinical benefit. 
CONCLUSION 
Brk has been implicated in tumorigenesis, survival and 
progression as well as diagnosis and prognosis of  breast 
cancer despite the fact there is no indication of  expres-
sion of  Brk in normal mammary tissue. Thus making it 
a viable target of  breast cancer therapy and an interest-
ing protein to investigate. Brk expression changes have 
not been associated with soley with an increase in ptk6 
gene copy number, which allows for study of  alternative 
mechanisms by which Brk expression and breast cancer 
develops. Ongoing research may still reveal more associa-
tions of  Brk with, as yet, uncharacterised substrates. A 
wider view of  Brk’s interacting proteins and substrates 
therefore will prove to be useful in developing anti-Brk 
therapies for breast cancers.
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